UROGEN PHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.91 USD | -2.34% |
|
-1.22% | -13.93% |
| May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
| May. 13 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
Chart calendar UroGen Pharma Ltd.
34dc8654.5xxKeeoO_4nu4Z06d_1s4Kx-RB9E3WZdOfAtIq2qyFI.s2UGLL1dvOjWiatvGqtdjoEwAU0ipB5tXLdJEfKaowDfWQYUgjmgy6OtzA~6db0b53435cfe4d3162fd6e95deb95af
Upcoming events on UroGen Pharma Ltd.
Past events on UroGen Pharma Ltd.
| 2024-05-20 09:00 am | H.C. Wainwright BioConnect Investor Conference |
| 2024-05-14 10:00 am | Citizens JMP Life Sciences Conference |
| 2024-05-13 10:00 am | Q1 2024 Earnings Call |
| 2024-05-13 08:00 am | Q1 2024 Earnings Release |
| 2024-05-05 12:20 pm | American Urological Association Meeting - Abstract No. 24-7534 |
| 2024-05-05 12:10 pm | American Urological Association Meeting - Abstract No. 24-7470 |
| 2024-05-04 03:20 pm | American Urological Association Meeting - Abstract No. 24-6641 |
| 2024-05-04 10:50 am | American Urological Association Meeting - Abstract No. 24-7720 |
| 2024-05-02 03:45 pm | AUA Innovation Nexus Conference |
| 2024-03-14 10:00 am | Q4 2023 Earnings Call |
| 2024-03-14 08:00 am | Q4 2023 Earnings Release |
| 2024-03-04 01:30 pm | TD Cowen Health Care Conference |
| 2024-02-13 12:00 pm | Oppenheimer Healthcare Life Sciences Conference |
| 2024-02-08 11:00 am | Guggenheim Healthcare Talks Biotechnology Conference |
| 2024-01-18 12:00 pm | B. Riley Securities Oncology Conference |
| 2023-11-30 02:15 pm | Society of Urologic Oncology Meeting - Poster Number #132 |
| 2023-11-30 12:04 pm | Society Of Urologic Oncology Meeting |
| 2023-11-14 10:00 am | Q3 2023 Earnings Call |
| 2023-11-14 08:00 am | Q3 2023 Earnings Release |
| 2023-09-26 08:45 am | Cantor Global Healthcare Conference - Fireside Chat |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,02 0,01 50% | 11,8 11,5 2.72% | 48,0 48,1 -0.13% | 64,4 64,8 -0.67% | 82,7 81,8 1.17% | 94,0 |
|
EBITDA Million USD | Released Forecast Spread | -109 -109 -0.58% | -126 -130 3.16% | -91,5 -90,2 -1.34% | -78,1 -73,2 -6.66% | -64,7 -64,0 -1.16% | -87,5 |
|
EBIT Million USD | Released Forecast Spread | -109 -106 -3.24% | -127 -131 3.08% | -92,3 -96,6 4.51% | -79,0 -76,4 -3.51% | -65,5 -64,3 -1.96% | -94,5 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -105 -101 -4.6% | -125 -127 1.51% | -109 -109 -0.01% | -108 -105 -3.06% | -98,3 -99,3 0.94% | -128 |
|
Net income Million USD | Released Forecast Spread | -105 -101 -3.6% | -128 -129 0.17% | -111 -109 -1.76% | -109 -105 -4.37% | -102 -98,9 -3.37% | -128 |
|
EPS USD | Released Forecast Spread | -5,12 -4,94 -3.72% | -5,90 -5,92 0.29% | -4,96 -4,84 -2.56% | -4,79 -4,50 -6.54% | -3,55 -3,54 -0.28% | -3,60 |
| Announcement Date | 02/03/20 | 18/03/21 | 21/03/22 | 16/03/23 | 14/03/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 13,6 15,2 -10.62% | 16,6 17,3 -3.9% | 16,1 20,1 -20.1% | 18,1 18,5 -2.25% | 17,2 17,1 0.6% | 21,1 20,1 5.06% | 20,9 20,0 4.1% | 23,5 22,6 4.26% | 18,8 21,4 -12.2% | 23,8 | 24,2 | 27,2 | 25,8 | 34,5 |
|
EBIT Million USD | Released Forecast Spread | -22,0 -24,0 8.53% | -18,7 -21,0 10.86% | -18,1 -18,9 4.15% | -20,3 -17,6 -15.31% | -22,0 -22,9 3.52% | -15,4 -17,5 12.23% | -13,5 -16,8 19.42% | -14,6 -13,4 -9.21% | -25,7 -20,4 -26.19% | -21,8 | -23,6 | -23,4 | -31,0 | -18,6 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -28,1 -31,3 10.22% | -26,7 -27,6 3.38% | -25,1 -27,1 7.38% | -28,2 -26,1 -7.89% | -30,2 -29,2 -3.33% | -24,1 -26,4 8.73% | -21,9 -25,9 15.41% | -22,2 -23,1 3.99% | -32,2 -30,1 -7.12% | -30,6 | -32,9 | -32,6 | -34,7 | -26,6 |
|
Net income Million USD | Released Forecast Spread | -28,4 -30,3 6.42% | -26,7 -27,5 3.08% | -25,8 -26,7 3.21% | -28,2 -25,3 -11.86% | -30,2 -29,7 -1.69% | -24,1 -26,3 8.15% | -21,9 -26,2 16.57% | -26,0 -22,7 -14.52% | -32,3 -30,3 -6.68% | -30,6 | -32,9 | -32,6 | -34,7 | -26,6 |
|
EPS USD | Released Forecast Spread | -1,25 -1,34 6.86% | -1,18 -1,30 9.23% | -1,13 -1,18 4.07% | -1,22 -1,08 -13.38% | -1,30 -1,31 0.61% | -1,03 -1,13 8.44% | -0,68 -0,85 19.76% | -0,72 -0,69 -5.11% | -0,97 -0,89 -9.3% | -0,87 | -0,90 | -0,88 | -0,90 | -0,77 |
| Announcement Date | 10/05/22 | 11/08/22 | 10/11/22 | 16/03/23 | 11/05/23 | 10/08/23 | 14/11/23 | 14/03/24 | 13/05/24 | - | - | - | - | - |
More events
Past sector events for UroGen Pharma Ltd.
| 2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
| 2024-05-16 07:46 am | BIOCON LIMITED: Q4 2024 Earnings Release |
| 2024-05-16 01:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
| 2024-05-15 08:05 am | THIRD HARMONIC BIO, INC.: Q1 2024 Earnings Release |
| 2024-05-15 07:00 am | CABALETTA BIO, INC.: Q1 2024 Earnings Release |
| 2024-05-14 | TAIMED BIOLOGICS INC.: Q1 2024 Earnings Release |
| 2024-05-15 04:01 pm | CELCUITY INC.: Q1 2024 Earnings Release |
| 2024-05-14 04:05 pm | ENLIVEN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-14 04:00 pm | ARCUTIS BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-14 08:00 am | IMMUNOME, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- URGN Stock
- Calendar UroGen Pharma Ltd.